---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-22-000082"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2022-06-03T23:59:59+00:00"
generated_at: "2026-06-25T04:48:43.190851+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics elects three Class II directors at 2022 annual meeting

## Summary
- Vicki Sato (65.5M for, 15.5M withheld), Erik Harris (80.6M for, 0.3M withheld), and Peter Klein (67.3M for, 13.6M withheld) elected as Class II directors.
- Ratification of Ernst & Young as independent auditor for FY2022 passed with 86.8M for, 16K against, 37K abstain.
- Non-binding advisory vote on executive compensation approved with 75.8M for, 4.5M against, 0.6M abstain.
- 70.70% of outstanding shares (86.9M of 122.9M) represented at the meeting.

## SEC filing metadata
- accession: 0001714899-22-000082
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2022-06-03T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000082/0001714899-22-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000082/dnli-20220602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-22-000082
- JSON: https://secwatch.observer/filing/0001714899-22-000082.json
- Plain text: https://secwatch.observer/filing/0001714899-22-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.